Huimin Wang - 08 Jul 2022 Form 4 Insider Report for Edwards Lifesciences Corp (EW)

Reporting relationship: CVP, Japan & Intercontinental
Issuer ticker: EW
Reported as of: 08 Jul 2022
Net transaction value: -$229,332
SEC form: 4
Accepted by SEC: 08 Jul 2022, 18:21:01 UTC
Prior SEC filing: 14 Jun 2022
Source filing: View source filing
Reporting owner signature: Linda J. Park, Attorney-in-Fact

Key filing fact

Huimin Wang filed Form 4 for Edwards Lifesciences Corp (EW) on 08 Jul 2022.

Key facts

This page summarizes Huimin Wang's Form 4 filing for Edwards Lifesciences Corp (EW).
3 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 08 Jul 2022, 18:21.

Change

Previous filing in this sequence was filed on 14 Jun 2022.
Current net transaction value: -$229,332.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

EW transaction

Common Stock

Options Exercise

Transaction value: $129,348
Shares: +3,675
Change %: +3.7%
Price: $35.20
Shares after: 103,056
Date: 08 Jul 2022
Ownership: Direct
Footnotes: F1

EW transaction

Common Stock

Sale

Transaction value: $358,680
Shares: -3,675
Change %: -3.6%
Price: $97.60
Shares after: 99,381
Date: 08 Jul 2022
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

EW transaction Derivative

Employee Stock Option (Right to Acquire)

Options Exercise

Transaction value: $0
Shares: -3,675
Change %: -12%
Price: $0.000000
Shares after: 25,725
Date: 08 Jul 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 3,675
Exercise price: $35.20

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 4, 2022.

SEC remarks

This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. This Form 4 includes quarterly acquisition of shares under the Issuer's Employee Stock Purchase Plan.